UCLB Marks 25 Years of Innovation2018-09-26T14:54:28+00:00

Project Description

UCLB Marks 25 Years of Innovation

As this year marks our 25th  anniversary, it provides the perfect time to look back on some of the remarkable achievements leading up to this point.

Our  journey initially began when we were established as Freemedic in 1993. Over this time, UCLB has proudly been nurturing the research and ideas of UCL academics into world-leading, world-changing technological innovations that have a real impact on people’s lives.

At UCLB we benchmark everything we do against the impact that we make on society. That’s why it’s rewarding to see so many UCL technologies solving industry problems and utilising research to treat patients. For example, Simulect ®, a monoclonal antibody being used to prevent rejection in organ transplantation, especially in kidney transplants. The Saphena® anti-embolism stocking is also being used throughout the NHS, providing a clinically effective system to help prevent the formation of Deep Vein Thrombosis (DVT). UCLB licensed the know-how and UCL trade mark behind this to Saphena® in 2003.

Endomagnetics, a UCL spinout created in 2007, is now pushing the boundaries of medical science, allowing radiologists to accurately mark the site of breast tumours up to 30 days before surgery to enable the precise removal and treatment of breast cancer. The medical device company was also recently recognised for its efforts towards cancer treatment, receiving The Queen’s Award for Innovation in Enterprise.

2008 saw the launch of UCL Computer Science spinout Chirp. Chirp uses innovative technology to enable peer-to-peer and online sharing of small amounts of information through sound. It has used its technology to find solutions across various industries from computer games to the energy sector. Most recently Chirp has partnered with Microsoft applying its sound based connectivity solution to connect Microsoft’s IoT devices to the Azure Cloud.

Over the years UCLB have provided funding advice to many academics and spinouts, connecting them with suitable opportunities. In 2016 the UCL Technology Fund was launched. The £50 million fund is co-managed by UCLB and Albion Capital, and invests in promising technologies arising from UCL. UCLB has also connected many academics to the Apollo Therapeutics fund, a unique collaboration between three global pharmaceutical companies: AstraZeneca, GlaxoSmithKline and Johnson & Johnson.

The past 25 years have seen some remarkable achievements for many UCLB spinouts and with some great success stories already this year, UCLB looks forward to working with many more of the future’s technologies.

Take a look at our 25th anniversary timeline to see just some of the stories from the last 25 years.

Discover More

UCLB Marks 25 Years of Innovation

UCLB Marks 25 Years of Innovation

2018 is a key milestone for UCLB as it marks 25 years since our incorporation as UCL’s technology commercialisation company, ...
Making decisions simple

Making decisions simple

Although crude search engines go back to the early 1990s, it wasn’t until 1998 that Google Search was made available ...
Even blue blood can be imperfect

Even blue blood can be imperfect

It’s not widely known that haemophilia was quite common amongst the royal families of Europe during 19th and 20th centuries ...
Is this breakthrough the nail in the coffin of lung cancer?

Is this breakthrough the nail in the coffin of lung cancer?

Without a doubt, there are a number of misconceptions surrounding lung cancer. The first, for example, concerns survival rates. The ...
Children are not small adults

Children are not small adults

When it comes to the use of medicines, children cannot be treated as small adults. Simply using existing solutions and ...
Sowing the seeds of change for breast cancer

Sowing the seeds of change for breast cancer

Detecting the spread of breast cancer (referred to as metastasis) is understandably a critically important step in the diagnosis, treatment ...